


Accepted Manuscript

Genipin inhibits the invasion and migration of colon cancer cells by the suppression of HIF-1 α accumulation and VEGF expression

Suk-young Lee, Hong Jun Kim, Sang Cheul Oh, Dae-Hee Lee



PII: S0278-6915(18)30207-2

DOI: [10.1016/j.fct.2018.04.005](https://doi.org/10.1016/j.fct.2018.04.005)

Reference: FCT 9694

To appear in: *Food and Chemical Toxicology*

Received Date: 16 October 2017

Revised Date: 30 March 2018

Accepted Date: 3 April 2018

Please cite this article as: Lee, S.-y., Kim, H.J., Oh, S.C., Lee, D.-H., Genipin inhibits the invasion and migration of colon cancer cells by the suppression of HIF-1 α accumulation and VEGF expression, *Food and Chemical Toxicology* (2018), doi: 10.1016/j.fct.2018.04.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Genipin inhibits the invasion and migration of colon cancer cells**
2 **by the suppression of HIF-1 α accumulation and VEGF expression**

3
4 Suk-young Lee^a, Hong Jun Kim^a, Sang Cheul Oh^{a,b}, Dae-Hee Lee^{a,b*}

5
6 ^aDepartment of Oncology, Korea University Guro Hospital, ^bGraduate School of Medicine,
7 Korea University College of Medicine, Seoul, Republic of Korea.

8 .
9 **Running title:** Genipin induced suppression of HIF-1 α accumulation

10
11 ***Correspondence to:**

12 Dae-Hee Lee, PhD.

13 Department of Oncology, Korea University Guro Hospital, Korea University Guro Hospital,
14 148 Gurodong-gil, Guro-gu, Seoul 152-703, Republic of Korea.

15 Phone: +82-2-2626-1998; Fax: +82-2-2626-1148

16 E-mail: neogene@korea.ac.kr

20 **Abstract**

21 Hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) play
22 important roles in cancer progression in various cancer cell lines. Although genipin, a
23 constituent of Gardenia fruit, has been shown to have anti-tumor activity, its role in the
24 suppression of HIF-1 and its downstream target genes is not well understood. We examined
25 the effect of genipin on the intracellular level of HIF-1 α and extracellular level of VEGF
26 using the colon cancer cell line HCT116. We observed that genipin suppressed the
27 accumulation of HIF-1 α under hypoxia in various cancer cell lines, including HCT116, via
28 the modulation of protein degradation. Genipin also suppressed the expression of VEGF and
29 the invasion of colon cancer cells by blocking the extracellular signal-regulated kinase
30 signaling pathway. Taken together, our results provide new insights into the potential role of
31 genipin in suppressing colon cancer progression.

32
33 **Keywords:** Genipin, Hypoxia-inducible factor-1, Vascular endothelial growth factor,
34 Invasion, Akt, ERK

35

36

37

38

39

40

41 1. Introduction

42 Although treatment outcomes have improved since the development of molecular targeted
43 agents in patients with metastatic colon cancer, there is still an unmet need for the
44 development of therapeutic agents owing to the limitations of current treatments.

45 Genipin, a metabolite derived from geniposide, is present in the fruit of *Gardenia*
46 *jasminoides* Ellis. Previous studies have identified various roles of genipin, e.g., as an anti-
47 inflammatory (Nam et al., 2010), anti-angiogenic (Park et al., 2003), anti-oxidative (Wang et
48 al., 2009), and anti-thrombotic (Suzuki et al., 2001) agent. In addition, a potential of genipin
49 as an anti-neoplastic agent has been suggested based on its ability to induce apoptosis and
50 suppress metastasis in various human cancer cell lines (Cao et al., 2010; Kim et al., 2005;
51 Wang et al., 2012) (Feng et al., 2011) (Hong and Kim, 2007).

52 Hypoxia, which is a common feature of the tumor cell environment in various cancers,
53 induces the activation of hypoxia-inducible factor-1 (HIF-1), a heterodimeric transcription
54 factor. HIF-1 is composed of two transactivation domains, the HIF-1 α and HIF-1 β subunits.
55 The α subunit usually forms a complex with the von Hippel-Lindau tumor suppressor protein,
56 leading to degradation via the ubiquitin-proteasome process under normoxic conditions. The
57 stability of HIF-1 α under hypoxia is controlled by several pathways, resulting in the
58 accumulation of HIF-1 α and dimerization with HIF-1 β . The HIF-1 α/β dimer subsequently
59 translocates to the nucleus and triggers the expression of downstream genes (Hicklin and
60 Ellis, 2005; Iliopoulos et al., 1996; Jaakkola et al., 2001; Maxwell and Ratcliffe, 2002;
61 Maxwell et al., 1999).

62 Vascular endothelial growth factor (*VEGF*), a downstream gene activated by HIF-1, plays a
63 salient role in angiogenesis. Signaling by the interaction between VEGF and its receptor,

64 VEGFR, promotes tumor growth and progression via the invasion, migration, proliferation,
65 and activation of endothelial cells and increased microvascular permeability (Choong and
66 Nadesapillai, 2003; Hicklin and Ellis, 2005; Zachary and Gliki, 2001). VEGF is associated
67 not only with endothelial cell migration and invasion, which are crucial steps in the early
68 phase of angiogenesis, but also with cancer cell invasion by inducing the expression of matrix
69 metalloproteinases (MMPs), urokinase plasminogen activator (uPA) and its receptor (uPAR),
70 and tissue-type plasminogen activator (Choong and Nadesapillai, 2003; Hicklin and Ellis,
71 2005; Krishnamachary et al., 2003; Zachary and Gliki, 2001). A previous study has reported
72 that hypoxia-induced HIF-1 α overexpression stimulates the Matrigel invasion of colon cancer
73 cells and triggers the expression of proteins involved in the pathophysiology of invasion
74 (Krishnamachary et al., 2003). Another study has also demonstrated that HIF-1 α
75 accumulation and VEGF expression via Akt/phosphoinositide 3-kinase (PI3K) and
76 extracellular signal-regulated kinase (ERK) 1/2 activation play a role in regulating hepatoma
77 and tongue cancer cell invasion (Zhang et al., 2005).

78 Despite abundant data related to the role of genipin in apoptosis, its anti-invasive
79 mechanism in cancers has been scarcely clarified. The activation of c-Jun NH₂-terminal
80 kinase (JNK) is a well-known mechanism underlying genipin-induced apoptosis in various
81 cancer cells, including breast cancer, prostate cancer, hepatoma, and cervical cancer cells
82 (Cao et al., 2010; Hong and Kim, 2007; Kim et al., 2005; Kim et al., 2012). The induction of
83 apoptosis by genipin is also thought to play an important role in suppressing hematologic
84 malignancies (Feng et al., 2011; Lee et al., 2011). On the other hand, only a few studies have
85 reported the effect of genipin on the inhibition of cancer invasion. In hepatocellular
86 carcinoma, the p38/TIMP-1/MMP-2 pathway is involved in the anti-metastatic effect of
87 genipin (Wang et al., 2012). The inhibition of cancer invasion by genipin has also been

88 confirmed in breast cancer cells via unclarified pathways (Gupta et al., 2013).

89 Given that one of suggested mechanisms underlying genipin-mediated anti-invasive activity
90 was the inhibition of MMP-2 via the p38/TIMP-1/MMP-2 pathway, we thought it would be
91 valuable to examine another possible mechanism for the inhibition of cancer invasion by
92 genipin. Many previous results have shown that hypoxia-induced HIF-1 and VEGF are
93 associated with the increased expression of MMP in cancer invasion (Gupta et al., 2013;
94 Krishnamachary et al., 2003; Lamoreaux et al., 1998; Zachary and Glick, 2001); accordingly,
95 we investigated if genipin exerts anti-invasive activity by the inhibition of the HIF-1/VEGF-
96 mediated expression of MMP in colon cancer cells. Here, our results provide important
97 information regarding the mechanism by which genipin inhibits cancer progression using a
98 human colon cancer cell line.

99

100 **2. Materials and methods**

101 2.1. Cell lines

102 Human colon cancer (HCT116 and HT29), human breast cancer (SKBR-3), and human
103 prostate cancer (DU145) cell lines were purchased from the Korea Cell Line Bank. To test for
104 mycoplasma contamination in all cells, we used the MycoAlert™ PLUS Mycoplasma
105 Detection Kit (Lonza, Allendale, NJ, USA). Human breast cancer SKBR-3 cells were
106 cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA). Human prostate cancer
107 DU145 cells and colon cancer HT29 cells were cultured in Dulbecco's modified Eagle's
108 medium (Gibco BRL, Gaithersburg, MD, USA). HCT116 colon cancer cells and HepG2 liver
109 cancer cells were cultured in McCoy's 5A medium (Invitrogen, Carlsbad, CA, USA). The
110 human colon cell line CCD-18Co and normal lung cell line Beas 2B were purchased from the

111 ATCC (Manassas, VA, USA). All cancer cell lines were cultured with 70% fetal bovine serum
112 (Hyclone, Logan, UT, USA) and 26 μ M sodium bicarbonate for monolayer cell culture under
113 a humidified atmosphere of 5% CO₂ in air at 37°C.

114 2.2. Hypoxia and treatment with reagents

115 Genipin, 99% purity, was purchased from Sigma-Aldrich (St. Louis, MO, USA) or
116 Selleckchem (Houston, TX, USA). Dimethyl sulfoxide (DMSO) was employed to increase
117 genipin solubility, which is greater in organic solvents than in phosphate-buffered saline.
118 Cycloheximide (CHX) and deferoxamine (DFX) were obtained from Calbiochem (San Diego,
119 CA, USA). Cells on Petri dishes were incubated in a hypoxic chamber (Forma Scientific,
120 Marietta, OH, USA) with a 94:5:1 mixture of N₂/CO₂/O₂ for hypoxia treatment.
121 Deoxygenated media were manufactured by equilibration with a hypoxic gas mixture
122 containing 5% CO₂, 94% N₂, and 1% O₂ at 37°C before each experiment. After reaching 70-
123 80% confluence, cells were prepared in complete media and treated with CHX and various
124 concentrations of genipin. Continual incubation was performed in normal culture conditions
125 under hypoxia exposure (1% O₂) during the indicated time intervals.

126 2.3. Survival assay

127 Cells were treated with MTS reagent for 3 h at 37°C in an atmosphere of 5% CO₂, and cell
128 viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
129 bromide (MTT) assay (Roche Life Science, San Francisco, CA, USA). Absorbance at 450 nm
130 was determined using an enzyme-linked immunosorbent assay (ELISA) plate reader.

131 2.4. Immunoblot assay

132 A western blot analysis was performed according to a protocol described previously (Gupta

133 et al., 2013). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel
134 electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. The membrane
135 was blocked with 5% non-fat dry milk in phosphate-buffered saline-Tween-20 (0.1%, v/v) for
136 1 h. The diluted primary antibodies were incubated with the membrane at 4°C for 1 h,
137 according to the manufacturers' instructions. Monoclonal antibodies were purchased from the
138 following companies: anti-HIF-1 α from BD Biosciences (San Jose, CA, USA), anti-actin
139 from ICN (Costa Mesa, CA, USA), and anti-Akt, anti-phospho-Ser⁴⁷³-Akt, anti-HSP90, anti-
140 ERK, anti-phospho-ERK, anti-MMP-2, anti-MMP-9, and anti-uPA from Cell Signaling
141 Technology (Beverly, MA, USA). Horseradish peroxidase-conjugated anti-rabbit or anti-
142 mouse IgG was used as the secondary antibody. Chemiluminescence (ECL; Amersham,
143 Arlington Heights, IL, USA) was used for the visualization of immunoreactive proteins.
144 Experiments were repeated at least three times for the immunoblotting assays. Densitometric
145 analysis was performed using a gel image analysis program, ImageJ (NIH, Bethesda, MD,
146 USA).

147 2.5. Transcriptional activation assay

148 A luciferase assay was carried out as described previously (Emerling et al., 2008). Cells
149 were transiently transfected with a luciferase reporter plasmid pGL2-hypoxia-response
150 element (HRE) and a reference luciferase plasmid pRL-CMV (Promega, Madison, WI, USA)
151 with FuGENE HD (Roche Diagnostics), according to the manufacturer's instructions.

152 2.6. Real-time polymerase chain reaction (RT-PCR)

153 Total RNA was extracted using TRIzol reagent (Life Technologies, Rockville, MD, USA)
154 according to the manufacturer's instructions. TaqMan primers from Life Technologies
155 Applied Biosystems (Foster City, CA, USA) were purchased and used to measure gene

156 expression (*HIF-1 α* , hypoxia-inducible factor-1: Hs00153153_m1; *VEGF*, vascular
157 endothelial growth factor: Hs00900055_m1; *GLUT1*, glucose transporter 1: Hs00892681_m1;
158 *CA9*, carbonic anhydrase 9: Hs00154208_s1; *GAPDH*, glyceraldehyde-3-phosphate
159 dehydrogenase: Hs03929097_g1). RT-PCR was performed using gene-specific TaqMan
160 probes on an Applied Biosystems StepOnePlus Real-Time PCR system with TaqMan PCR
161 Master Mix (Life Technologies).

162 2.7. ELISA

163 HCT116 cells (1×10^5) were plated on a 60-mm plate in RPMI medium and incubated
164 overnight before treatment. The cell culture medium was removed and stored at -80°C .
165 Determination of VEGF levels in the media was carried out by ELISA using a commercial kit
166 (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol, as
167 described previously (Gupta et al., 2013).

168 2.8. Invasion assay

169 Twenty-four-well BD BioCoat Growth Factor-Reduced Matrigel Invasion Chambers (BD
170 Biosciences, Bedford, MA, USA) were used for Transwell invasion experiments. The
171 invasion chambers consisted of a BD Falcon® cell culture insert with an 8- μm pore size
172 polyethylene terephthalate (PET) membrane coated with BD Matrigel Matrix, which serves
173 as a reconstituted basement membrane *in vitro*. HCT116 cells exposed to hypoxia were
174 prepared for the cell suspension in serum-free culture medium at 1×10^5 cells without or with
175 genipin according to the concentration gradient. Membranes with cells attached to the lower
176 membrane surface (invaded cells) were fixed with methanol and stained with hematoxylin.
177 Invasiveness was determined by counting the number of invaded cells under a microscope at
178 100x magnification. Results are presented as the average number of cell per filter of triplicate

179 experiments.

180 2.9. Statistical analysis

181 Statistical significance was calculated using Student's *t*-tests. The two-sample *t*-test was
182 used for two-group comparisons. Values are reported as means \pm standard deviation (SD). A
183 value of $p < 0.05$ was considered significant.

184

185 3. Results

186 3.1. Genipin inhibits the accumulation of HIF-1 α under hypoxia in human colon cancer cells

187 Genipin is a chemical compound with anti-tumor activity (Fig. 1A) (Cao et al., 2010; Feng
188 et al., 2011; Hong and Kim, 2007; Kim et al., 2005; Roux and Blenis, 2004). We investigated
189 the effects of co-treatment with genipin and hypoxia on the viability of normal cell lines
190 (colon and lung). We found that co-treatment with genipin and normoxia or hypoxia does not
191 induce cell death in either cell line (Fig. 1B). To determine whether genipin exerts a cytotoxic
192 effect in colon cells by inhibiting HIF-1 α accumulation, an MTS assay was performed using
193 HCT116 colon cancer cells treated with various concentrations of genipin under hypoxic
194 conditions. Cell viability was measured in an environment of 1% oxygen with 5 to 200 μ M
195 genipin. Decreased viability was observed after 24 h of incubation with 200 μ M genipin (Fig.
196 1C). We found no significant change in colon cancer cell viability after treatment with 50 μ M
197 genipin for 8 h (Fig. 1C), but HIF-1 α protein accumulation increased after exposure to
198 hypoxia for 8 h (Fig. 1D). Furthermore, HIF-1 α accumulation as well as the phosphorylation
199 of Akt were suppressed by 50 μ M genipin (Fig. 1E), suggesting that genipin had a minimal
200 effect on viability in HCT116 cells. The suppression of HIF-1 α accumulation was also

201 observed in various cancer cells, such as liver, prostate, colon, and breast cancer, treated with
202 a low concentration (50 μ M) of genipin under hypoxia (Fig. 2A–D).

203 3.2. Genipin-induced suppression of *HIF-1 α* accumulation via the modulation of protein 204 degradation

205 An HRE promoter-luciferase reporter assay using HCT116 cells was performed to evaluate
206 the transcriptional activity of *HIF-1 α* in response to hypoxia after treatment with genipin.
207 Decreased luciferase activity was observed in cells treated with 50 μ M genipin under hypoxia
208 (Fig. 3A) as well as in cells treated with a combination of 50 μ M genipin and DFX, another
209 known HIF-1 inducer, under normoxic conditions (Fig. 3B). We did not observe a change in
210 the mRNA expression of *HIF-1 α* after genipin treatment under hypoxia, but decreased mRNA
211 expression levels of other hypoxic markers, such as *VEGF*, *GLUT1*, and *CA9*, were observed
212 (Fig. 3C). Because genipin had little effect of the mRNA expression of *HIF-1 α* , we evaluated
213 if genipin modulates protein expression. We observed that suppressed HIF-1 α protein
214 expression was more prominent in HCT116 cells treated with a combination of genipin and
215 CHX than in those treated with CHX alone under hypoxia (Fig. 4A, B). Suppressed HIF-1 α
216 accumulation was also observed in colon cancer cells treated with a combination of MG132
217 and genipin (Fig. 4C), suggesting that genipin is involved in the modulation of HIF-1 α
218 protein degradation.

219 3.3. Genipin leads to the suppression of *VEGF* expression and invasion of colon cancer cells 220 by inhibiting the ERK signaling pathway

221 Given that VEGF is a downstream target of HIF-1 α (Hicklin and Ellis, 2005), ELISA was
222 performed to determine the extracellular levels of VEGF in the presence of genipin. We
223 found that the expression of VEGF decreased as the concentration of genipin increased under

224 hypoxia (Fig. 5A). Because VEGF induces the expression of proteins involved in cell
225 invasion, such as MMP and uPA (Choong and Nadesapillai, 2003; Ferrara and Davis-Smyth,
226 1997; Hicklin and Ellis, 2005), we evaluated the role of genipin in the migration and invasion
227 of colon cancer cells. Dose-dependent inhibition of cancer cell invasion was detected in
228 HCT116 cells treated with genipin under hypoxia by an invasion assay (Fig. 5B). We next
229 examined the expression levels of MMP-2, MMP-9, and uPA by western blotting in genipin-
230 treated HCT116 cells under hypoxia. Reduced expression of these proteins was confirmed in
231 the presence of genipin. Interestingly, the expression level of phosphorylated ERK was also
232 decreased by treatment with genipin, suggesting that the genipin-induced suppression of
233 invasion could be mediated by blocking the ERK signaling pathway (Fig. 5C, D).

234

235 **4. Discussion**

236 Owing to the limited number of effective therapeutic agents for metastatic colon cancer,
237 there has been a persistent need for the development of novel agents. HIF-1 is involved in
238 cancer progression by promoting angiogenesis and metastasis, and these effects are mediated
239 by VEGF under hypoxia (Hicklin and Ellis, 2005). Although targeting HIF-1 has been of
240 great interest given its significant role in tumor progression, no clinically available HIF-1
241 inhibitors have been developed. However, several studies have suggested that
242 chemoprevention may be possible using natural products, such as phenethyl isothiocyanate,
243 apigenin, or chrysin, in various cancers by showing the suppression of HIF-1 α and VEGF
244 (Emerling et al., 2008; Fang et al., 2007; Fu et al., 2007; Gupta et al., 2013).

245 Genipin has also been regarded as a potential chemopreventive natural product based on its
246 cancer suppressive effect. Previous studies have demonstrated that the metabolic pathway of

247 genipin is a benign crosslinking agent that strengthens the mechanical properties of tissues
248 (Reich and Akkus, 2013). Another study has found genipin sulfate as a major metabolite of
249 geniposide; however, it may not be permeable through the intestinal membrane and seems
250 indispensable to be hydrolyzed to lipophilic genipin in the intestinal lumen before absorption
251 (Akao et al., 1994; Hou et al., 2008). Here, we showed that genipin inhibits the accumulation
252 of HIF-1 α under hypoxia in various human cancer cell lines, including colon cancer. The
253 suppression of HIF-1 α as well as proteins involved in cancer invasion was accompanied by
254 the decreased expression of phospho-Akt and phospho-ERK, suggesting that the detrimental
255 effect of HIF-1 α was mediated by the Akt/PI3K and ERK 1/2 signaling pathways. New vessel
256 formation is a critical process in tumor progression, and targeting signaling by VEGF and its
257 receptor is one of the most important treatment options for several cancers. Given the
258 inhibitory effect of genipin on VEGF, genipin might act on colon cancer cells to inhibit
259 angiogenesis synergistically with agents targeting VEGF or VEGFR. In addition, since Akt
260 and ERK1/2 are downstream signaling mediators of epidermal growth factor receptor
261 (EGFR), it is possible that genipin has an inhibitory effect on EGFR. Monoclonal antibodies
262 targeting EGFR are another core axis in the treatment of colon cancer, along with anti-
263 angiogenesis agents; accordingly, further studies on the possible role of genipin in blocking
264 EGFR activation might provide another potential novel therapeutic agent in colon cancer.

265 Interestingly, the inhibitory activity of genipin on HIF-1 was not mediated by the
266 suppression of transcription, but by the modulation of protein degradation. In addition, our
267 results showed that genipin inhibited HIF-1 α activity both under hypoxia and DFX treatment,
268 suggesting a highly specific property of genipin against HIF-1 α , regardless of the hypoxic
269 condition, i.e., physiological or chemical (Chau et al., 2005).

270 These findings provide new insights into mechanisms by which genipin suppresses the

271 invasive capacity of colon cancer cells. Genipin inhibited HIF-1 α accumulation and VEGF
272 expression, subsequently resulting in the decreased expression of MMP and uPA, proteins
273 associated with basement membrane degradation, under hypoxia. HIF-1 α and VEGF have
274 been reported to be biomarkers for the advanced stage of colon cancer. A previous study has
275 reported that metastasis of colon cancer cells to the liver is significantly associated with the
276 expression of HIF-1 α and VEGF, as indicated by immunohistochemical staining of tissues
277 from patients with colon cancer (Cao et al., 2009). In addition, many *in vitro* studies have
278 highlighted the role of HIF-1 in promoting metastasis of colon cancer cells (van der Bilt et al.,
279 2007; Zhang et al., 2014; Zhao et al., 2010). Although many natural products have been
280 shown to have the inhibitory effect on cancer migration, the inhibitory mechanism for genipin
281 has not been clarified. Our previous study demonstrated that Akt and ERK inhibitors have
282 synergistic effects with a natural product in inactivating those proteins (Gupta et al., 2013),
283 suggesting that the anti-cancer effect of genipin combined with other targeted agents should
284 be explored further.

285 In summary, we presented clear results suggesting a novel role of genipin in the suppression
286 of cancer progression using a colon cancer cell line. Genipin inhibited hypoxia- and DFX-
287 induced HIF-1 α accumulation and VEGF expression via the modulation of protein
288 degradation. Genipin also inhibited cancer invasion as indicated by the suppressed expression
289 of MMP and uPA. The Akt/PI3K and ERK 1/2 signaling pathways were involved in the
290 suppression of HIF-1 α expression and cancer invasion.

291

292 **Funding**

293 This work was supported by grants from the National Research Foundation (NRF) of Korea,

294 funded by the Korean government (MSIP) [NRF-2015R1D1A1A01058303], and the Korea
295 Health Technology R&D Project through the Korea Health Industry Development Institute
296 (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number:
297 HI15C1665)

298

299 **Conflicts of interest**

300 The authors declare no conflicts of interest.

301

302 **References**

303 Akao, T., Kobashi, K., Aburada, M., 1994. Enzymic studies on the animal and intestinal
304 bacterial metabolism of geniposide. *Biol Pharm Bull* 17, 1573-1576.

305 Cao, D., Hou, M., Guan, Y.S., Jiang, M., Yang, Y., Gou, H.F., 2009. Expression of HIF-
306 1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic
307 implications. *BMC Cancer* 9, 432.

308 Cao, H., Feng, Q., Xu, W., Li, X., Kang, Z., Ren, Y., Du, L., 2010. Genipin induced apoptosis
309 associated with activation of the c-Jun NH2-terminal kinase and p53 protein in HeLa cells.
310 *Biol Pharm Bull* 33, 1343-1348.

311 Chau, N.M., Rogers, P., Aherne, W., Carroll, V., Collins, I., McDonald, E., Workman, P.,
312 Ashcroft, M., 2005. Identification of novel small molecule inhibitors of hypoxia-inducible
313 factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible
314 factor-1alpha induction in response to hypoxic stress and growth factors. *Cancer Res* 65,
315 4918-4928.

316 Choong, P.F., Nadesapillai, A.P., 2003. Urokinase plasminogen activator system: a

- 317 multifunctional role in tumor progression and metastasis. *Clin Orthop Relat Res*, S46-58.
- 318 Emerling, B.M., Weinberg, F., Liu, J.L., Mak, T.W., Chandel, N.S., 2008. PTEN regulates
319 p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead
320 transcription factor 3a (FOXO3a). *Proc Natl Acad Sci U S A* 105, 2622-2627.
- 321 Fang, J., Zhou, Q., Liu, L.Z., Xia, C., Hu, X., Shi, X., Jiang, B.H., 2007. Apigenin inhibits
322 tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. *Carcinogenesis* 28,
323 858-864.
- 324 Feng, Q., Cao, H.L., Xu, W., Li, X.R., Ren, Y.Q., Du, L.F., 2011. Apoptosis induced by
325 genipin in human leukemia K562 cells: involvement of c-Jun N-terminal kinase in G(2)/M
326 arrest. *Acta Pharmacol Sin* 32, 519-527.
- 327 Ferrara, N., Davis-Smyth, T., 1997. The biology of vascular endothelial growth factor. *Endocr*
328 *Rev* 18, 4-25.
- 329 Fu, B., Xue, J., Li, Z., Shi, X., Jiang, B.H., Fang, J., 2007. Chrysin inhibits expression of
330 hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability
331 and inhibiting its protein synthesis. *Mol Cancer Ther* 6, 220-226.
- 332 Gupta, B., Chiang, L., Chae, K., Lee, D.H., 2013. Phenethyl isothiocyanate inhibits hypoxia-
333 induced accumulation of HIF-1alpha and VEGF expression in human glioma cells. *Food*
334 *Chem* 141, 1841-1846.
- 335 Hicklin, D.J., Ellis, L.M., 2005. Role of the vascular endothelial growth factor pathway in
336 tumor growth and angiogenesis. *J Clin Oncol* 23, 1011-1027.
- 337 Hong, H.Y., Kim, B.C., 2007. Mixed lineage kinase 3 connects reactive oxygen species to c-
338 Jun NH2-terminal kinase-induced mitochondrial apoptosis in genipin-treated PC3 human
339 prostate cancer cells. *Biochem Biophys Res Commun* 362, 307-312.
- 340 Hou, Y.C., Tsai, S.Y., Lai, P.Y., Chen, Y.S., Chao, P.D., 2008. Metabolism and

- 341 pharmacokinetics of genipin and geniposide in rats. *Food Chem Toxicol* 46, 2764-2769.
- 342 Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G., Jr., Goldberg, M.A., 1996. Negative
343 regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. *Proc Natl Acad Sci*
344 U S A 93, 10595-10599.
- 345 Jaakkola, P., Mole, D.R., Tian, Y.M., Wilson, M.I., Gielbert, J., Gaskell, S.J., von Kriegsheim,
346 A., Hebestreit, H.F., Mukherji, M., Schofield, C.J., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J.,
347 2001. Targeting of HIF- α to the von Hippel-Lindau ubiquitylation complex by O₂-
348 regulated prolyl hydroxylation. *Science* 292, 468-472.
- 349 Kim, B.C., Kim, H.G., Lee, S.A., Lim, S., Park, E.H., Kim, S.J., Lim, C.J., 2005. Genipin-
350 induced apoptosis in hepatoma cells is mediated by reactive oxygen species/c-Jun NH₂-
351 terminal kinase-dependent activation of mitochondrial pathway. *Biochem Pharmacol* 70,
352 1398-1407.
- 353 Kim, E.S., Jeong, C.S., Moon, A., 2012. Genipin, a constituent of *Gardenia jasminoides* Ellis,
354 induces apoptosis and inhibits invasion in MDA-MB-231 breast cancer cells. *Oncol Rep* 27,
355 567-572.
- 356 Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N.,
357 LaRusch, J., Pak, B., Taghavi, P., Semenza, G.L., 2003. Regulation of colon carcinoma cell
358 invasion by hypoxia-inducible factor 1. *Cancer Res* 63, 1138-1143.
- 359 Lamoreaux, W.J., Fitzgerald, M.E., Reiner, A., Hasty, K.A., Charles, S.T., 1998. Vascular
360 endothelial growth factor increases release of gelatinase A and decreases release of tissue
361 inhibitor of metalloproteinases by microvascular endothelial cells in vitro. *Microvasc Res* 55,
362 29-42.
- 363 Lee, J.C., Ahn, K.S., Jeong, S.J., Jung, J.H., Kwon, T.R., Rhee, Y.H., Kim, S.H., Kim, S.Y.,
364 Yoon, H.J., Zhu, S., Chen, C.Y., Kim, S.H., 2011. Signal transducer and activator of

- 365 transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
366 *J Cell Biochem* 112, 1552-1562.
- 367 Maxwell, P.H., Ratcliffe, P.J., 2002. Oxygen sensors and angiogenesis. *Semin Cell Dev Biol*
368 13, 29-37.
- 369 Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E.,
370 Wykoff, C.C., Pugh, C.W., Maher, E.R., Ratcliffe, P.J., 1999. The tumour suppressor protein
371 VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* 399, 271-
372 275.
- 373 Nam, K.N., Choi, Y.S., Jung, H.J., Park, G.H., Park, J.M., Moon, S.K., Cho, K.H., Kang, C.,
374 Kang, I., Oh, M.S., Lee, E.H., 2010. Genipin inhibits the inflammatory response of rat brain
375 microglial cells. *Int Immunopharmacol* 10, 493-499.
- 376 Park, E.H., Joo, M.H., Kim, S.H., Lim, C.J., 2003. Antiangiogenic activity of *Gardenia*
377 *jasminoides* fruit. *Phytother Res* 17, 961-962.
- 378 Reich, M.S., Akkus, O., 2013. Sporicidal efficacy of genipin: a potential theoretical
379 alternative for biomaterial and tissue graft sterilization. *Cell Tissue Bank* 14, 381-393.
- 380 Roux, P.P., Blenis, J., 2004. ERK and p38 MAPK-activated protein kinases: a family of
381 protein kinases with diverse biological functions. *Microbiol Mol Biol Rev* 68, 320-344.
- 382 Suzuki, Y., Kondo, K., Ikeda, Y., Umemura, K., 2001. Antithrombotic effect of geniposide
383 and genipin in the mouse thrombosis model. *Planta Med* 67, 807-810.
- 384 van der Bilt, J.D., Soeters, M.E., Duyverman, A.M., Nijkamp, M.W., Witteveen, P.O., van
385 Diest, P.J., Kranenburg, O., Borel Rinkes, I.H., 2007. Perinecrotic hypoxia contributes to
386 ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. *Am J Pathol* 170,
387 1379-1388.
- 388 Wang, G.F., Wu, S.Y., Rao, J.J., Lu, L., Xu, W., Pang, J.X., Liu, Z.Q., Wu, S.G., Zhang, J.J.,

- 389 2009. Genipin inhibits endothelial exocytosis via nitric oxide in cultured human umbilical
390 vein endothelial cells. *Acta Pharmacol Sin* 30, 589-596.
- 391 Wang, N., Zhu, M., Tsao, S.W., Man, K., Zhang, Z., Feng, Y., 2012. Up-regulation of TIMP-1
392 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human
393 hepatocellular carcinoma. *PLoS One* 7, e46318.
- 394 Zachary, I., Gliki, G., 2001. Signaling transduction mechanisms mediating biological actions
395 of the vascular endothelial growth factor family. *Cardiovasc Res* 49, 568-581.
- 396 Zhang, Q., Tang, X., Lu, Q.Y., Zhang, Z.F., Brown, J., Le, A.D., 2005. Resveratrol inhibits
397 hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in
398 human tongue squamous cell carcinoma and hepatoma cells. *Mol Cancer Ther* 4, 1465-1474.
- 399 Zhang, W., Wu, Y., Yan, Q., Ma, F., Shi, X., Zhao, Y., Peng, Y., Wang, J., Jiang, B., 2014.
400 Deferoxamine enhances cell migration and invasion through promotion of HIF-1alpha
401 expression and epithelial-mesenchymal transition in colorectal cancer. *Oncol Rep* 31, 111-116.
- 402 Zhao, X.Y., Chen, T.T., Xia, L., Guo, M., Xu, Y., Yue, F., Jiang, Y., Chen, G.Q., Zhao, K.W.,
403 2010. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in
404 migration/invasion of colorectal cancer cells. *Carcinogenesis* 31, 1367-1375.

405

406

407

408

409

410

411

412

413

414 **Figure legends**415 **Fig. 1.** Effect of genipin under hypoxia on the intracellular level of HIF-1 α in HCT116 cells.

416 (A) Structure of genipin. (B) Effect of genipin on the viability of normal cells was determined

417 by MTS assays. The normal cell lines (CCD-18Co (colon) and Beas 2B (lung)) were treated

418 with 50 μ M genipin for 24 h. (C) Effect of genipin on the viability of HCT116 cells was

419 determined by MTS assays. Error bars represent standard errors of the mean (SEM) from

420 three independent experiments. (D) Kinetics of HIF-1 α protein accumulation under hypoxia.421 (E) Dose-dependent inhibition of HIF-1 α protein accumulation and Akt phosphorylation after

422 treatment with various concentrations of genipin. Beta-actin was used as a loading control.

423

424 **Fig. 2.** Effect of genipin on HIF-1 α protein accumulation under hypoxic conditions in various

425 cancer cell lines. (A) HepG2, (B) DU145, (C) HT29, and (D) SkBr3 cells were cultured

426 under hypoxic conditions alone or were treated with 50 μ M genipin and cultured under

427 hypoxia. Cell lysates with equal amounts of proteins were loaded and separated by SDS-

428 PAGE and immunoblotted with an anti-HIF-1 α antibody. Beta-actin was used as a loading

429 control.

430

431 **Fig. 3.** Measurement of the transcriptional activity and mRNA expression of *HIF-1 α* . (A) The432 transcriptional activity of *HIF-1 α* was measured by the luciferase assay after treatment with

433 various concentrations of genipin under hypoxia. Luciferase activity is presented as the mean
434 \pm SD of three independent experiments. Asterisks indicate statistically significant differences
435 in mean values compared to untreated HCT116 cells ($*p < 0.05$, $**p < 0.001$). (B) The
436 transcriptional activity of *HIF-1 α* was measured after treatment with genipin (left) and DFX
437 (right) under normoxic conditions. Error bars represent SEM from three independent
438 experiments. The asterisk indicates a statistically significant difference compared to untreated
439 HCT116 cells ($*p < 0.05$). (C) mRNA expression levels of *HIF-1 α* and various hypoxic
440 markers were measured by RT-PCR under normoxia (left) and hypoxia (right) in the presence
441 or absence of genipin. Error bars represent SEM from three independent experiments. A
442 statistically significant difference is indicated by an asterisk ($*p < 0.05$).

443


444 **Fig. 4.** Time-dependent effect of CHX and genipin on the accumulation of HIF-1 α under
445 hypoxia in HCT116 colon cancer cells. (A) HCT116 cells were treated with CHX alone (left)
446 or CHX combined with genipin (right) under hypoxia. (B) Time-dependent expression of
447 HIF-1 α after treatment with CHX alone or CHX combined with genipin under hypoxia. The
448 lower panel shows HIF-1 α signal levels quantified by densitometry, and values are expressed
449 as percentage expression relative to that of untreated cells at the indicated time points. Error
450 bars represent SEM from three independent experiments. The asterisk indicates a statistically
451 significant difference ($*p < 0.05$). (C) Dose-dependent inhibition of HIF-1 α accumulation
452 after treatment with various concentrations of genipin with or without MG132 under hypoxia.
453 Beta-actin was used as a loading control.

454

455 **Fig. 5.** The mechanism underlying the anti-invasive effect of genipin on HCT116 colon

456 cancer cells. (A) Suppression of extracellular VEGF expression by genipin in a dose-
457 dependent manner under hypoxia was measured by ELISA. Results are presented by the
458 mean values of VEGF concentrations, and error bars represent SEM from three independent
459 experiments. (B) Invasion parameters are indicated as means \pm SD of three separate
460 experiments. Statistically significant differences were determined by Student's *t*-tests. The
461 mean values denoted by asterisks indicate significant differences compared to the matched
462 HCT116 cells without treatment with genipin ($*p < 0.05$, $**p < 0.01$). (C) The expression
463 levels of invasion-related proteins and p-ERK 1/2 relative to that of actin are indicated as
464 means \pm SD of three independent experiments. The mean values denoted with an asterisk and
465 sharp indicate statistically significant difference compared to the matched normoxic control
466 and hypoxic control, respectively. Statistical significance was determined by Student's *t*-tests
467 ($*p < 0.05$, $\#p < 0.001$). (D) Decreased expression of invasion-related proteins and p-ERK
468 1/2 after treatment with genipin under hypoxia based on an immunoblotting assay. Beta-actin
469 was used as a loading control.

470






Fig. 2A, 2B, 2C, and 2D




Fig. 3A, 3B, and 3C




Fig. 4A, 4B, and 4C




Fig. 5A, 5B, 5C, and 5D

Highlights

- Genipin inhibits accumulation of HIF-1 α and VEGF expression in human colon cancer.
- Genipin exerts anti-invasion effect on human colon cancer cells.
- Genipin-induced anti-cancer effect is exerted by Akt and ERK signaling pathways.